TME Pharma N.V.

TME Pharma N.V. is a clinical-stage biopharmaceutical company focused on developing proprietary cancer therapeutics in Germany. Its Spiegelmer platform includes a pipeline of clinical-stage candidates, led by NOX-A12, which is in mid-stage development as a combination therapy for cancer indications such as metastatic pancreatic and colorectal cancer and glioblastoma. The company is also developing NOX-E36, which has completed a Phase 1/2 clinical trial for diabetic nephropathy. Formerly known as NOXXON Pharma N.V., it changed its name to TME Pharma N.V. in July 2022, was founded in 1997, and is headquartered in Berlin, Germany.